Natco Pharma Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 4,97,871 shares,. Its Average Traded Price (ATP) is ₹785.74, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 1 @ ₹785.05.
Natco Pharma has an upper circuit limit of ₹942.05 and a lower circuit limit of ₹628.05. The total value traded stands at ₹39.12 CR, and the delivery percentage for the day is 65.07%.
The stock is currently traded with a market lot size of 1. Natco Pharma also offers a dividend yield of 0.63%.
Natco Pharma Share Price Chart
Natco Pharma Share Key Metrics
Volume
4.98 L
Market Cap
15400.17 CR
LTQ@LTP
1@785.05
ATP
785.74
Var Margin
17.85 %
Circuit Range
628.05-942.05
Delivery %
65.07 %
Value
39.12 CR
ASM/GSM
No
Market Lot
1
Natco Pharma Resistance and Support
Pivot 783.85
Resistance
First Resistance
788.7
Second Resistance
792.45
Third Resistance
797.3
Support
First Support
780.1
Second Support
775.25
Third Support
771.5
Natco Pharma Shareholding Pattern
View More- 2018-19
- 2019-20
- 2021-22
- 2020-21
- 2025-26
- 2024-25
- 2022-23
- 2023-24
- 2026-27
Total Promoters
Natco Pharma Corporate Actions
| Date | Agenda |
|---|---|
| 2026-09-25 | Rights issue of Equity Shares |
| 2026-09-09 | Fund Raising |
| 2026-08-14 | Quarterly Results & Interim Dividend |
| 2026-05-29 | Audited Results |
| 2026-03-24 | Scheme of Arrangement |
| 2026-02-12 | Quarterly Results & Interim Dividend |
| 2025-11-14 | Quarterly Results & Interim Dividend |
| 2025-08-12 | Quarterly Results & Interim Dividend |
| 2025-05-28 | Audited Results |
| 2025-02-12 | Quarterly Results & Interim Dividend |
| 2024-11-12 | Quarterly Results & Interim Dividend |
| 2024-08-12 | Quarterly Results & Interim Dividend |
| Ex Date | Record Date | |
|---|---|---|
| 2026-08-20 | 2026-08-20 | View More |
| Rights Date | Ratio | |
|---|---|---|
| 2026-10-01 | 2:21 | View More |
Natco Pharma News
Natco Pharma Ltd - 524816 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Promoter V.C. Nannapaneni has created a pledge on 8.5 lakh equity shares, representing 0.47% of Natco Pharma's total share capital. The pledge was created in favor of Bajaj Financial Securities Limited.
Oct 13 2026 10:28:23
Natco Pharma Ltd - 524816 - Board Meeting Outcome for Outcome Of Fund Raising Committee Meeting Approving The Letter Of Offer For Rights Issue
Natco Pharma's fund-raising committee approved the Letter of Offer for a rights issue of up to 1.70 crore equity shares. The issue size is Rs.1,279.40 crore at a price of Rs.750 per share in the ratio of 2:21. The record date for the issue has been fixed as October 1, 2026.
Sep 28 2026 20:52:17
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco Pharma has increased its investment in US-based biotechnology firm eGenesis from $14.00 million to $16.70 million. The investment is being executed through its Canadian and US subsidiaries via convertible promissory notes, bringing the total investment in eGenesis to $24.70 million.
Sep 28 2026 14:58:45
Natco Pharma Ltd - 524816 - Intimation Of Record Date For Rights Issue
Natco Pharma set October 1, 2026, as the Record Date for its Rights Issue. This date will determine shareholders eligible to receive Rights Entitlements.
Sep 25 2026 11:25:43
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Issue of Securities
Natco Pharma's board approved a Rights Issue to raise up to Rs.1,279.36 crore. The company will offer 1.70 crore shares at Rs.750 per share, with a record date of October 1, 2026. The issue will open on October 12, 2026.
Sep 25 2026 11:19:26
Natco Pharma Ltd - 524816 - Board Meeting Outcome for Out Come Of Board Meeting
Natco Pharma board approved a rights issue to raise ₹1279.36 crore. The company will issue 1.71 crore equity shares at ₹750 each with a face value of ₹2, setting the record date for October 1, 2026. The rights ratio is 2 shares for every 21 held.
Sep 25 2026 11:18:01
Natco Pharma Ltd - 524816 - Receipt Of In-Principal Approval For Rights Issue Of Equity Shares
Natco Pharma secured in-principle approval from NSE and BSE for its Rights Issue on September 21, 2026. This allows the company to proceed with issuing fully paid-up equity shares.
Sep 21 2026 22:44:15
Natco Pharma Management
| Name | Position |
|---|---|
| Chekuri Venkat Ramesh | Company Secretary & Compliance Officer |
| V C Nannapaneni | Chairman & Managing Director |
Natco Pharma Similar Stocks
Molbio Diagnostics Ltd.
1574.40
145.10 (10.15%)
Onesource Specialty Pharma Ltd.
1407.80
-25.40 (1.77%)
Poly Medicure Ltd.
1593.80
10.00 (0.63%)
Eris Lifesciences Ltd.
1144.40
-4.40 (0.38%)
Alembic Pharmaceuticals Ltd.
789.45
-3.20 (0.40%)
Jubilant Pharmova Ltd.
938.60
0.40 (0.04%)
Dr. Agarwal's Health Care Ltd.
465.80
-11.35 (2.38%)
Concord Biotech Ltd.
1339.00
-14.30 (1.06%)
Vijaya Diagnostic Centre Ltd.
1381.70
-5.70 (0.41%)
Marksans Pharma Ltd.
311.00
3.15 (1.02%)
Natco Pharma FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in NATCOPHARM
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in NATCOPHARM
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade